Mabwell (Shanghai) Bioscience Co Ltd Class A 688062
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor
-
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
-
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA
-
FDA Grants Orphan Drug Designation to 7MW3711
-
Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC
-
FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 62.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,402
- Website
- https://www.mabwell.com
Comparables
Valuation
|
Metric
|
688062
|
300149
|
688278
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 37.92 |
Price/Book Value | 4.43 | 2.17 | 12.78 |
Price/Sales | 62.41 | 2.76 | 10.76 |
Price/Cash Flow | — | 22.49 | 34.36 |
Price/Earnings
688062
300149
688278
Financial Strength
|
Metric
|
688062
|
300149
|
688278
|
|---|---|---|---|
Quick Ratio | 1.53 | 1.46 | 3.14 |
Current Ratio | 1.78 | 1.71 | 4.07 |
Interest Coverage | −32.55 | −32.05 | 1,553.17 |
Quick Ratio
688062
300149
688278
Profitability
|
Metric
|
688062
|
300149
|
688278
|
|---|---|---|---|
Return on Assets (Normalized) | −24.26% | −34.73% | 30.63% |
Return on Equity (Normalized) | −41.90% | −54.47% | 37.49% |
Return on Invested Capital (Normalized) | −26.98% | −38.80% | 37.06% |
Return on Assets
688062
300149
688278
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tnclzmhyw | Dlfn | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ttzplljfk | Myfzmsx | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qkpklnq | Yxgznf | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Stxxjbsf | Yqwcgc | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Fpsgyjbx | Tkxgx | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ytqnhglz | Nqm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Nwdqsbhj | Yqr | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Hbrhnbny | Kjyr | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wccftcqzl | Nryrhbq | $13.4 Bil | |||
| Incyte Corp
INCY
| Fsyttms | Wnntpd | $12.7 Bil |
United States